185 related articles for article (PubMed ID: 8570727)
1. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland.
Lee LK; Whitehurst C; Pantelides ML; Moore JV
Photochem Photobiol; 1995 Nov; 62(5):882-6. PubMed ID: 8570727
[TBL] [Abstract][Full Text] [Related]
2. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy.
Aniola J; Selman SH; Lilge L; Keck R; Jankun J
Int J Mol Med; 2003 Mar; 11(3):287-91. PubMed ID: 12579328
[TBL] [Abstract][Full Text] [Related]
3. In vivo laser light distribution in human prostatic carcinoma.
Whitehurst C; Pantelides ML; Moore JV; Brooman PJ; Blacklock NJ
J Urol; 1994 May; 151(5):1411-5. PubMed ID: 8158797
[TBL] [Abstract][Full Text] [Related]
4. Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT.
Lilge L; Pomerleau-Dalcourt N; Douplik A; Selman SH; Keck RW; Szkudlarek M; Pestka M; Jankun J
Phys Med Biol; 2004 Jul; 49(14):3209-25. PubMed ID: 15357193
[TBL] [Abstract][Full Text] [Related]
5. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.
Jankun J; Lilge L; Douplik A; Keck RW; Pestka M; Szkudlarek M; Stevens PJ; Lee RJ; Selman SH
J Urol; 2004 Aug; 172(2):739-43. PubMed ID: 15247773
[TBL] [Abstract][Full Text] [Related]
6. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.
Selman SH; Albrecht D; Keck RW; Brennan P; Kondo S
J Urol; 2001 May; 165(5):1795-801. PubMed ID: 11342978
[TBL] [Abstract][Full Text] [Related]
7. Laser dosimetry studies in the prostate.
Chen Q; Hetzel FW
J Clin Laser Med Surg; 1998 Feb; 16(1):9-12. PubMed ID: 9728124
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers.
Lilge L; Wilson BC
J Clin Laser Med Surg; 1998 Apr; 16(2):81-91. PubMed ID: 9663099
[TBL] [Abstract][Full Text] [Related]
9. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
[TBL] [Abstract][Full Text] [Related]
10. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy.
Jankun J; Keck RW; Skrzypczak-Jankun E; Lilge L; Selman SH
BJU Int; 2005 Jun; 95(9):1237-44. PubMed ID: 15892808
[TBL] [Abstract][Full Text] [Related]
11. Interstitial photodynamic therapy in the canine prostate.
Lee LK; Whitehurst C; Chen Q; Pantelides ML; Hetzel FW; Moore JV
Br J Urol; 1997 Dec; 80(6):898-902. PubMed ID: 9439405
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
13. Light penetration in bladder tissue: implications for the intravesical photodynamic therapy of bladder tumours.
Shackley DC; Whitehurst C; Moore JV; George NJ; Betts CD; Clarke NW
BJU Int; 2000 Oct; 86(6):638-43. PubMed ID: 11069369
[TBL] [Abstract][Full Text] [Related]
14. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
15. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies.
Moshfeghi DM; Peyman GA; Moshfeghi AA; Khoobehi B; Primbs GB; Crean DH
Ophthalmic Surg Lasers; 1998 Aug; 29(8):663-8. PubMed ID: 9715492
[TBL] [Abstract][Full Text] [Related]
16. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2).
Peyman GA; Moshfeghi DM; Moshfeghi A; Khoobehi B; Doiron DR; Primbs GB; Crean DH
Ophthalmic Surg Lasers; 1997 May; 28(5):409-17. PubMed ID: 9150524
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy of the ciliary body with tin ethyl etiopurpurin and tin octaethyl benzochlorin in pigmented rabbits.
Hill RA; Crean DH; Doiron DR; Ghosheh F; Ryan JA; Kelly H; Booth M; Liaw LH; Newman L; Berns MW
Ophthalmic Surg Lasers; 1997 Nov; 28(11):948-53. PubMed ID: 9387183
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland.
Pantelides ML; Whitehurst C; Moore JV; King TA; Blacklock NJ
J Urol; 1990 Feb; 143(2):398-401. PubMed ID: 2299739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
